Recommended Citation
Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, Alikhan A, Daveluy SD, Delorme I, Goldfarb N, Gulliver W, Hamzavi I, Jaleel T, Kimball AB, Kirby JS, Kirchhof Md MG, Lester J, Lev-Tov H, Lowes MA, Micheletti R, Orenstein LA, Piguet V, Sayed C, Tan J, and Naik HB. Comorbidity screening in Hidradenitis Suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol 2021.
Document Type
Article
Publication Date
1-22-2021
Publication Title
Journal of the American Academy of Dermatology
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk.
OBJECTIVE: To provide evidence-based screening recommendations for comorbidities linked to HS.
METHODS: Systematic reviews were performed to summarize evidence on prevalence and incidence of 30 comorbidities in HS patients relative to the general population. Screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence and magnitude of association, as well as benefits, harms, and feasibility of screening. Level of evidence and strength of corresponding screening recommendation were graded using SORT criteria.
RESULTS: Screening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovarian syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis and sexual dysfunction. It is also recommended to screen Down syndrome patients for HS. Decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity.
LIMITATIONS: Screening recommendations represent one component of a comprehensive care strategy.
CONCLUSIONS: Dermatologists should support screening efforts to identify comorbid conditions in HS.
PubMed ID
33493574
ePublication
ePub ahead of print
